Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 2a dose-finding study of NLY01 (PEGylated exenatide) in type 2 diabetes
2019-000398-21Phase 2Completed
- Sponsor
- Neuraly
- Start
- Aug 2019
- Modality
- Peptides, Biodegradable Polymers → Polymer-based Nanoparticles → Nanoparticles → Drug Delivery Systems
- Countries
- 1
01
Overview
Phase 2, single-arm trial of pegsebrenatide in type 2 diabetes mellitus (T2DM), sponsored by Neuraly. Primary endpoint: Safety endpoints (primary). Started Aug 2019; status: completed.
02
Drugs
pegsebrenatide
03
Conditions
type 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on 2019-000398-21.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2019-000398-21.